133 related articles for article (PubMed ID: 38296557)
1. A Structure-Activity Relationship Study of SNAIL1 Peptides as Inhibitors of Lysine-Specific Demethylase 1.
Takada Y; Adachi K; Fujinaga Y; Yamashita Y; Itoh Y; Suzuki T
Chem Pharm Bull (Tokyo); 2024; 72(2):155-160. PubMed ID: 38296557
[TBL] [Abstract][Full Text] [Related]
2. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
Ota Y; Kakizawa T; Itoh Y; Suzuki T
Molecules; 2018 May; 23(5):. PubMed ID: 29734782
[TBL] [Abstract][Full Text] [Related]
4. Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics.
Baby S; Shinde SD; Kulkarni N; Sahu B
ACS Chem Biol; 2023 Oct; 18(10):2144-2155. PubMed ID: 37812385
[TBL] [Abstract][Full Text] [Related]
5. Histone H3 peptide based LSD1-selective inhibitors.
Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
[TBL] [Abstract][Full Text] [Related]
6. The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1.
Lin Y; Wu Y; Li J; Dong C; Ye X; Chi YI; Evers BM; Zhou BP
EMBO J; 2010 Jun; 29(11):1803-16. PubMed ID: 20389281
[TBL] [Abstract][Full Text] [Related]
7. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
[TBL] [Abstract][Full Text] [Related]
8. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
Kakizawa T; Ota Y; Itoh Y; Suzuki T
Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
[TBL] [Abstract][Full Text] [Related]
9. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase.
Tortorici M; Borrello MT; Tardugno M; Chiarelli LR; Pilotto S; Ciossani G; Vellore NA; Bailey SG; Cowan J; O'Connell M; Crabb SJ; Packham G; Mai A; Baron R; Ganesan A; Mattevi A
ACS Chem Biol; 2013 Aug; 8(8):1677-82. PubMed ID: 23721412
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors.
Culhane JC; Wang D; Yen PM; Cole PA
J Am Chem Soc; 2010 Mar; 132(9):3164-76. PubMed ID: 20148560
[TBL] [Abstract][Full Text] [Related]
11. Covalent Peptide LSD1 Inhibitor Specifically Recognizes Cys360 in the Enzyme-Active Region.
Luo Q; Ma Y; Liang H; Feng Y; Liu N; Lian C; Zhu L; Ye Y; Liu Z; Hou Z; Chen S; Wang Y; Dai C; Song C; Zhang M; He Z; Xing Y; Zhong W; Li S; Wu J; Lu F; Yin F; Li Z
J Med Chem; 2023 Nov; 66(22):15409-15423. PubMed ID: 37922441
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
Schulz-Fincke J; Hau M; Barth J; Robaa D; Willmann D; Kürner A; Haas J; Greve G; Haydn T; Fulda S; Lübbert M; Lüdeke S; Berg T; Sippl W; Schüle R; Jung M
Eur J Med Chem; 2018 Jan; 144():52-67. PubMed ID: 29247860
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
[TBL] [Abstract][Full Text] [Related]
14. Identifying the novel inhibitors of lysine-specific demethylase 1 (LSD1) combining pharmacophore-based and structure-based virtual screening.
Sun XD; Zheng YC; Ma CY; Yang J; Gao QB; Yan Y; Wang ZZ; Li W; Zhao W; Liu HM; Ding L
J Biomol Struct Dyn; 2019 Oct; 37(16):4200-4214. PubMed ID: 30366512
[TBL] [Abstract][Full Text] [Related]
15. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective.
Dai XJ; Liu Y; Xiong XP; Xue LP; Zheng YC; Liu HM
J Med Chem; 2020 Dec; 63(23):14197-14215. PubMed ID: 32931269
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new tetrahydroisoquinolines as potent and selective LSD1 inhibitors for the treatment of MLL-rearranged leukemia.
Yang C; Fang Y; Hu Y; Tian T; Liao G
Eur J Med Chem; 2023 Sep; 257():115516. PubMed ID: 37257211
[TBL] [Abstract][Full Text] [Related]
17. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate.
Schmitt ML; Ladwein KI; Carlino L; Schulz-Fincke J; Willmann D; Metzger E; Schilcher P; Imhof A; Schüle R; Sippl W; Jung M
J Biomol Screen; 2014 Jul; 19(6):973-8. PubMed ID: 24687155
[TBL] [Abstract][Full Text] [Related]
19. Human histone demethylase LSD1 reads the histone code.
Forneris F; Binda C; Vanoni MA; Battaglioli E; Mattevi A
J Biol Chem; 2005 Dec; 280(50):41360-5. PubMed ID: 16223729
[TBL] [Abstract][Full Text] [Related]
20. Molecular mimicry and ligand recognition in binding and catalysis by the histone demethylase LSD1-CoREST complex.
Baron R; Binda C; Tortorici M; McCammon JA; Mattevi A
Structure; 2011 Feb; 19(2):212-20. PubMed ID: 21300290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
